Nisha Pandey

CagriSema Beats Lilly’s Mounjaro & Zepbound In New Trial: All About Novo’s Next-Gen Obesity Drug

Novo Nordisk's next-generation obesity drug CagriSema has delivered greater weight loss than a lower dose of Eli Lilly's tirzepatide in a new late-stage trial. The trial has given giving the Danish drugmaker new evidence for its upcoming weight loss injectable as it competes in the rapidly expanding GLP-1 obesity drug market.

In the Phase 3 REIMAGINE 5 trial, adults with type 2 diabetes receiving CagriSema lost an estimated 12.4% of their body weight after 60 weeks, compared with 9.1% among those receiving 5 mg of tirzepatide, the active ingredient in Lilly's Mounjaro and Zepbound. CagriSema also resulted reduction in HbA1c, a measure of average blood sugar.

However, the trial compared 1 mg/1 mg CagriSema to 5 mg tirzepatide, rather than the highest doses used in obesity treatment. Earlier this year, a separate Phase 3 trial in people with obesity found that CagriSema did not meet its goal against high-dose 15 mg tirzepatide. At 84 weeks, CagriSema resulted in 23% weight loss compared to 25.5% with tirzepatide. 

<a href="https://www.healthandme.com/health-wellness/ozempic-wegovy-pmos-how-glp-1-drugs-are-changing-pmos-treatment-article-156170141" data-type="tilCustomLink">CagriSema</a> is a once-weekly injection that combines two active ingredients: semaglutide and cagrilintide.

Semaglutide is the active ingredient in Novo's <a href="https://www.healthandme.com/health-news/glp-1-drugs-mounjaro-zepbound-show-promise-for-1-billion-with-sleep-apnea-article-156140963" data-type="tilCustomLink">Wegovy and Ozempic</a>. It belongs to the GLP-1 receptor agonist class and helps reduce appetite and food intake. Cagrilintide mimics amylin, a hormone involved in appetite regulation and feelings of fullness. By combining the two medicines, Novo is attempting to produce greater weight loss results.

Unlike Wegovy and Ozempic, however, CagriSema is still investigational. Novo submitted it to the US FDA for weight management in December 2025. The regulatory decision is expected in the fourth quarter of 2026.

Also read: <a href="https://www.healthandme.com/health-news/hundreds-of-american-glp-1-users-sue-novo-nordisk-eli-lilly-over-vision-loss-what-is-naion-article-156200838" data-type="tilCustomLink">Hundreds Of American GLP-1 Users Sue Novo Nordisk, Eli Lilly Over Vision Loss: What Is NAION?</a>

REIMAGINE 5 is based on adults with type 2 diabetes whose blood sugar was not controlled properly with metformin, an SGLT2 inhibitor or both. After 60 weeks, CagriSema showed 12.4% average weight loss. Tirzepatide 5 mg resulted in 9.1% average weight loss. 

CagriSema showed 1.71% HbA1c reduction while <a href="https://www.healthandme.com/health-news/ozempic-wegovy-mounjaro-and-zepbound-may-fuel-rare-brain-disorder-study-finds-article-156158570" data-type="tilCustomLink">tirzepatide</a> resulted in 1.67%.

Novo said the combination was generally well tolerated. Gastrointestinal side effects are among the common adverse effects that were seen with the treatment. 

Novo's chief scientific officer Martin Holst Lange called the findings “very encouraging” and said they strengthen the company's confidence in CagriSema's potential.

Also read: <a href="https://www.healthandme.com/health-news/blood-test-that-could-detect-50-cancers-closer-to-approval-as-fda-raises-no-major-concerns-about-its-accuracy-article-156199951" data-type="tilCustomLink">Blood Test That Could Detect 50+ Cancers Closer To Approval As FDA Raises No Major Concerns About Its Accuracy</a>

<h2>Is CagriSema Better Than Mounjaro Or Zepbound? </h2>

Sports Stars, Junk Food & Sugary Drinks: How Marketing Impacts Health

The new study establishes that CagriSema outperformed 5 mg tirzepatide for weight loss in this particular population sample with <a href="https://www.healthandme.com/health-wellness/world-patient-safety-day-why-insulin-innovation-in-diabetes-care-demands-an-ecosystem-approach-article-156172445" data-type="tilCustomLink">type 2 diabetes</a>.

But tirzepatide is available at substantially higher doses, and the earlier obesity head-to-head trial compared CagriSema with 15 mg tirzepatide, where tirzepatide produced better weight loss results. 

Therefore, the company has not declared that CagriSema consistently produces more weight loss than tirzepatide across all trials. 

CagriSema is Novo's attempt to move beyond single-pathway GLP-1 treatment by combining GLP-1 and amylin biology. In another new Phase 3 trial, REDEFINE 9, CagriSema produced 21% weight loss after 68 weeks, compared with 2% with placebo, in adults with overweight or obesity.

Health Conditions A-Z

health

cagrisema-beats-lillys-mounjaro-zepbound-in-new-trial-all-about-novos-next-gen-obesity-drug

Novo Nordisk

CagriSema

tirzepatide

semaglutide

cagrilintide

wegovy and ozempic

semaglutide weight loss

Ozempic

mounjaro

can-vitamin-d-levels-affect-hair-health

Can Vitamin D Levels Affect Hair Health?

preeclampsia-may-end-with-pregnancy-your-heart-risk-may-not

Preeclampsia May End With Pregnancy. Your Heart Risk May Not

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Novo Nordisk's next-generation obesity drug CagriSema has delivered greater weight loss than a lower dose of Eli Lilly's tirzepatide in a new late-stage trial. The trial has given giving the Danish drugmaker new evidence for its upcoming weight loss injectable as it competes in the rapidly expanding GLP-1 obesity drug market. In the Phase 3 REIMAGINE 5 trial, adults with type 2 diabetes receiving CagriSema lost an estimated 12.4% of their body weight after 60 weeks, compared with 9.1% among those receiving 5 mg of tirzepatide, the active ingredient in Lilly's Mounjaro and Zepbound. CagriSema also resulted reduction in HbA1c, a measure of average blood sugar. However, the trial compared 1 mg/1 mg CagriSema to 5 mg tirzepatide, rather than the highest doses used in obesity treatment. Earlier this year, a separate Phase 3 trial in people with obesity found that CagriSema did not meet its goal against high-dose 15 mg tirzepatide. At 84 weeks, CagriSema resulted in 23% weight loss compared to 25.5% with tirzepatide. What Is CagriSema? CagriSema is a once-weekly injection that combines two active ingredients: semaglutide and cagrilintide. Semaglutide is the active ingredient in Novo's Wegovy and Ozempic. It belongs to the GLP-1 receptor agonist class and helps reduce appetite and food intake. Cagrilintide mimics amylin, a hormone involved in appetite regulation and feelings of fullness. By combining the two medicines, Novo is attempting to produce greater weight loss results. Unlike Wegovy and Ozempic, however, CagriSema is still investigational. Novo submitted it to the US FDA for weight management in December 2025. The regulatory decision is expected in the fourth quarter of 2026.Also read: Hundreds Of American GLP-1 Users Sue Novo Nordisk, Eli Lilly Over Vision Loss: What Is NAION?What Did The New Trial Find? REIMAGINE 5 is based on adults with type 2 diabetes whose blood sugar was not controlled properly with metformin, an SGLT2 inhibitor or both. After 60 weeks, CagriSema showed 12.4% average weight loss. Tirzepatide 5 mg resulted in 9.1% average weight loss. CagriSema showed 1.71% HbA1c reduction while tirzepatide resulted in 1.67%. Novo said the combination was generally well tolerated. Gastrointestinal side effects are among the common adverse effects that were seen with the treatment. Novo's chief scientific officer Martin Holst Lange called the findings “very encouraging” and said they strengthen the company's confidence in CagriSema's potential.Also read: Blood Test That Could Detect 50+ Cancers Closer To Approval As FDA Raises No Major Concerns About Its AccuracyIs CagriSema Better Than Mounjaro Or Zepbound?                                  The new study establishes that CagriSema outperformed 5 mg tirzepatide for weight loss in this particular population sample with type 2 diabetes. But tirzepatide is available at substantially higher doses, and the earlier obesity head-to-head trial compared CagriSema with 15 mg tirzepatide, where tirzepatide produced better weight loss results. Therefore, the company has not declared that CagriSema consistently produces more weight loss than tirzepatide across all trials. CagriSema is Novo's attempt to move beyond single-pathway GLP-1 treatment by combining GLP-1 and amylin biology. In another new Phase 3 trial, REDEFINE 9, CagriSema produced 21% weight loss after 68 weeks, compared with 2% with placebo, in adults with overweight or obesity.

cagrisema beats lilly’s mounjaro & zepbound in new trial: all about novo’s next-gen obesity drug

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

CagriSema Beats Lilly’s Mounjaro & Zepbound In New Trial: All About Novo’s Next-Gen Obesity Drug

Hundreds Of American GLP-1 Users Sue Novo Nordisk, Eli Lilly Over Vision Loss: What Is NAION?

US FDA Moves Away From Animal Testing: How Organoids, AI & Organs-On-Chips Could Impact Drug Research

Vitamin D & Pregnancy: Could Vitamin D Deficiency Increase Risk Of Premature Birth?

Health Conditions A-Z

Can Vitamin D Levels Affect Hair Health?

CagriSema Beats Lilly’s Mounjaro & Zepbound In New Trial: All About Novo’s Next-Gen Obesity Drug

Preeclampsia May End With Pregnancy. Your Heart Risk May Not